"Brain-Computer Interfaces (BCIs) are revolutionizing industries like healthcare, gaming, and education by enabling thought-controlled devices, opening up new business opportunities...
The multi-year collaboration enables expanded access to quality diagnostic care for patients in California and provides Sutter physicians and clinicians...
The multi-year collaboration enables expanded access to quality diagnostic care for patients in California and provides Sutter physicians and clinicians...
The multi-year collaboration enables expanded access to quality diagnostic care for patients in California and provides Sutter physicians and clinicians...
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology...
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY,...
New findings support the company's neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized depression treatment PALO ALTO, Calif.,...
8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025...
LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- AI Wellness (Assisted Intelligence Wellness) is taking center stage at CES 2025 with Mission...
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the...
UW Medicine and Next Steps Chicago both purchased systems in late December 2024 ARC-EX is the first and only FDA approved...
The partnership reached initial go-live in three weeks, showcasing the impressive speed and scalability of Aidoc's aiOS™ platform HARTFORD, Conn.,...
ZURICH and NESS ZIONA, Israel, Jan. 8, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical...
~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for...
Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & DevelopmentBASEL, Switzerland,...
BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Software upgrade advances complete workflow solutions New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X,...
New claims-sourced RADAR models demonstrate positive predictive value BOSTON, Jan. 7, 2025 /PRNewswire/ -- Together Senior Health (Together), a Linus Health...
The Keynote Address, entitled "Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD," will be presented at 10:30AM PT...
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription...